FRAT2 Antikörper (Frequently Rearranged in Advanced T-Cell Lymphomas 2) (Cy5)

Details for Product anti-FRAT2 Antibody No. ABIN1704660
Antigen
  • FRAT2
  • FRAT2, WNT signaling pathway regulator
  • frequently rearranged in advanced T cell lymphomas 2
  • frequently rearranged in advanced T-cell lymphomas 2
  • FRAT2
  • Frat2
Reaktivität
Human, Maus, Ratte (Rattus)
51
14
14
Wirt
Kaninchen
33
16
1
1
Klonalität
Polyklonal
Konjugat
Dieser FRAT2 Antikörper ist konjugiert mit Cy5
4
4
4
3
3
3
1
1
1
1
1
1
1
1
1
1
Applikation
Immunofluorescence (Paraffin-embedded Sections) (IF (p))
38
27
17
17
12
7
6
1
1
Optionen
Immunogen KLH conjugated synthetic peptide derived from human FRAT2
Isotyp IgG
Reinigung Purified by Protein A.
Plasmids, Primers & others Plasmide, Primers & weitere FRAT2 products on genomics-online (e.g. as negative or positive controls)
Antigen
Andere Bezeichnung Frat2 (FRAT2 Antibody Abstract)
Hintergrund

FRAT1 and FRAT2 were originally characterized as proteins frequently rearranged in advanced T cell lymphoma, and they have since been identified as proto-oncogenes involved in tumorigenesis. These proteins share significant homology with the Xenopus glycogen synthase kinase-3 (xGSK-3) binding protein, which is designated GBP and is essential for the formation of the dorsal-ventral axis during embryonic development. Establishment of these embryonic axes is mediated by the Wnt intracellular signaling pathway. Wnt signaling is regulated in part by the activity of GSK-3, which phosphorylates and thereby facilitates the degradation of ?catenin. GBP binds to GSK-3 and inhibits this phosphorylation, resulting in the accumulation of ?catenin and the subsequent transcription of Wnt target genes. Like GBP, FRAT2 has been shown to bind xGSK-3, suggesting that FRAT1 and FRAT2 may be GSK-3 regulatory proteins.

Synonyms: Frequently rearranged in advanced T-cell lymphomas 2 antibodyGSK-3 binding protein FRAT2, FRAT2_HUMAN.

Gen-ID 23401
Applikations-hinweise IF(IHC-P) 1:50-200
Beschränkungen Nur für Forschungszwecke einsetzbar
Format Liquid
Konzentration 1 μg/μL
Buffer Aqueous buffered solution containing 1 % BSA, 50 % glycerol and 0.09 % sodium azide.
Konservierungs-mittel Sodium azide
Vorsichtsmaßnahmen This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
Lagerung 4 °C
Informationen zur Lagerung Store at 4°C
Haltbarkeit 12 months
Haben Sie etwas anderes gesucht?